Management of peritoneal carcinomatosis from colorectal cancer.
Management of peritoneal carcinomatosis from colorectal cancer.
复制标题
DOI：
10.1053/j.seminoncol.2011.05.011
复制
发表时间：
2011-08
影响因子：
4
通讯作者：
Levine EA
中科院分区：
文献类型：
--
作者：
Ihemelandu CU;Shen P;Stewart JH;Votanopoulos K;Levine EA
结直肠癌所致腹膜癌病的治疗方法正在发展。新的化疗药物和生物制剂的引入无疑改善了许多转移性结直肠癌患者的前景。传统上，肝或肺转移有限的患者是唯一的转移切除候选者。然而，转移到腹膜的患者已被证明是转移性切除术的候选对象，临床结果有所改善。在这组患者中，细胞减少术加热疗(HIPEC)提供了唯一的长期生存机会。完全细胞减灭术联合HIPEC治疗腹膜表面疾病已被证明可产生类似于肝切除治疗肝转移瘤的生存结果。这篇综述将审查有关不断发展的外科肿瘤学范例来处理结直肠腹膜癌病的最新证据。
The management of peritoneal carcinomatosis from colorectal cancer is evolving. The introduction of new chemotherapeutic and biologic agents has certainly improved the outlook for many patients with metastatic colorectal cancer. Traditionally, patients with limited hepatic or pulmonary metastases were the only candidates for metastasectomy. However, patients with metastasis localized to the peritoneum have been shown to be candidates for metastasectomy with improved clinical outcomes. Cytoreductive surgery with the addition of hyperthermic intraperitoneal chemotherapy (HIPEC) in this cohort of patients offers the only chance for long-term survival. Complete cytoreduction in combination with HIPEC for peritoneal surface disease has been demonstrated to produce survival outcomes similar to liver resection for hepatic metastases. This review will examine recent evidence pertaining to the evolving surgical oncology paradigm for management of colorectal peritoneal carcinomatosis.
登录
查看更多内容
影响因子：
3.7
作者：
Esquivel, J.;Sticca, R.;Sebbag, G.
通讯作者：
Sebbag, G.
影响因子：
50.5
作者：
Elias, D;Bonnay, A;Ducreux, M
通讯作者：
Ducreux, M
影响因子：
1.9
作者：
Gertsch, Philippe
通讯作者：
Gertsch, Philippe
影响因子：
45.3
作者：
Goldberg, Richard M.;Sargent, Daniel J.;Alberts, Steven
通讯作者：
Alberts, Steven
DOI：
10.1016/j.jamcollsurg.2006.12.048
发表时间：
2007-05-01
影响因子：
5.2
作者：
Levine, Edward A.;Stewart, John H., IV;Shen, Perry
通讯作者：
Shen, Perry